Global Blood Therapeutics Continues To Build Strong Case For Successful Commercialization

|
About: Global Blood Therapeutics, Inc. (GBT)
by: Real Finance
This article is exclusive for subscribers.
Real Finance
Long only, value, biotech, Growth
Summary

Company is guiding pre-NDA before end of Q1 2019 and will have more clarity on its confirmatory study design.

Investors should be looking forward to the Q2 2019 top-line results from the full HOPE Study. There are additional 117 patients that will have their data presented.

Commercialization plan is underway and GBT will be first to capture a $3-billion sickle cell disease market.

Compassionate patients won't stop taking the drug, and these patients have been on drug for more than two years.

Global Blood Therapeutics' Drug is Effective - No Doubt

To refresh investors' memory, Global Blood Therapeutics (GBT) released positive data from a Phase 3 clinical trial, HOPE, evaluating voxelotor in patients at least